Unicycive Therapeutics(UNCY)

Focus: Unicycive is a public biotechnology company focused on nephrology treatments, specifically targeting chronic kidney disease requiring dialysis. The company operates as a lean, pre-revenue stage biotech with minimal commercial infrastructure.

Nephrology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Unicycive Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Unicycive Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$675K

Pipeline & Clinical Trials

Oxylanthanum Carbonate

Chronic Kidney Disease Requiring Chronic Dialysis

PHASE_2

Clinical Trials (1)

NCT06218290A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

Phase 2

Help build intelligence for Unicycive Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused mission in underserved nephrology market with significant unmet need in dialysis-dependent CKD
Public company status provides equity upside potential and institutional credibility
Lean organization structure offers exposure across multiple functional areas for early-career professionals

Watch Out For

Severe cash burn ($36.7M net loss in FY2025) against minimal revenue ($675K in FY2024) creates sustainability risk with only $26M cash on hand
Zero active job postings and pre-revenue status suggest minimal hiring; recent news includes investor litigation warnings indicating stock volatility and shareholder concerns
Single Phase 2 program with no Phase 3 data or near-term FDA catalyst limits clinical validation and revenue visibility

Generated by Claude from Unicycive Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Nephrology

Publications: 6 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$20M55%

Net Income

-$37M

Cash

$26M

Source: SEC 10-K Filing

Research Publications(6)

Recent peer-reviewed publications with author affiliations at this company

UNI-494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L-NAME and angiotensin II.

Physiological reports

2025

PMID:41162192

A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia.

Clinical journal of the American Society of Nephrology : CJASN

Showing 5 of 6 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo